Skip to main content
Journal cover image

Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients' preference-based study (PPPS).

Publication ,  Journal Article
Zhao, Y; Qiao, G; Wang, X; Song, Y; Zhou, X; Jiang, N; Zhou, L; Huang, H; Zhao, J; Morse, MA; Hobeika, A; Ren, J; Lyerly, HK
Published in: Clin Transl Oncol
June 2019

BACKGROUND: Advanced non-small cell lung cancer (NSCLC) has remained challenging to treat effectively. This study aimed to investigate the clinical effects and safety of immunotherapy with dendritic cells and cytokine-induced killer cells (DC-CIK) administered with chemotherapy (CT) in this malignancy. METHODS: We have developed a new clinical trial design termed as the prospective patient's preference-based study (PPPS). Consecutive patients (n = 135) with advanced NSCLC were treated with DC-CIK administered with CT or mono-therapy (CT or DC-CIK alone). RESULTS: For all the patients, the median PFS was 5.7 months and the median OS was 17.5 months. The 1-year PFS and OS rates were 29.4% and 58.2%, respectively. The 1-year PFS and OS rates for DC-CIK plus CT were significantly higher than that in the group of patients who received DC-CIK alone and CT alone (P < 0.05). The number of adoptively infused DC-CIK cells was associated with clinical efficacy. After adjusting for competing risk factors, DC-CIK combined with CT and infused number of CIKs remained independent predictors of PFS and OS. Phenotypic analysis of peripheral blood mononuclear cells showed that CD8+CD28+, and CD8+CD28- T cells, changed significantly in all groups (P < 0.01). The CD3+ T cells increased in the chemotherapy plus immunotherapy and the immunotherapy alone group (P < 0.01), while CD3-CD16+CD56 T cells decreased in the chemotherapy plus immunotherapy and the immunotherapy alone group (P < 0.01). CONCLUSIONS: DC-CIK combined with chemotherapy administration resulted in numerically superior PFS and OS compared with monotherapy in advanced NSCLC.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Transl Oncol

DOI

EISSN

1699-3055

Publication Date

June 2019

Volume

21

Issue

6

Start / End Page

721 / 728

Location

Italy

Related Subject Headings

  • T-Lymphocytes
  • Survival Rate
  • Prospective Studies
  • Prognosis
  • Patient Preference
  • Oncology & Carcinogenesis
  • Middle Aged
  • Male
  • Lung Neoplasms
  • Immunotherapy, Adoptive
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Zhao, Y., Qiao, G., Wang, X., Song, Y., Zhou, X., Jiang, N., … Lyerly, H. K. (2019). Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients' preference-based study (PPPS). Clin Transl Oncol, 21(6), 721–728. https://doi.org/10.1007/s12094-018-1968-3
Zhao, Y., G. Qiao, X. Wang, Y. Song, X. Zhou, N. Jiang, L. Zhou, et al. “Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients' preference-based study (PPPS).Clin Transl Oncol 21, no. 6 (June 2019): 721–28. https://doi.org/10.1007/s12094-018-1968-3.
Zhao, Y., et al. “Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients' preference-based study (PPPS).Clin Transl Oncol, vol. 21, no. 6, June 2019, pp. 721–28. Pubmed, doi:10.1007/s12094-018-1968-3.
Zhao Y, Qiao G, Wang X, Song Y, Zhou X, Jiang N, Zhou L, Huang H, Zhao J, Morse MA, Hobeika A, Ren J, Lyerly HK. Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients' preference-based study (PPPS). Clin Transl Oncol. 2019 Jun;21(6):721–728.
Journal cover image

Published In

Clin Transl Oncol

DOI

EISSN

1699-3055

Publication Date

June 2019

Volume

21

Issue

6

Start / End Page

721 / 728

Location

Italy

Related Subject Headings

  • T-Lymphocytes
  • Survival Rate
  • Prospective Studies
  • Prognosis
  • Patient Preference
  • Oncology & Carcinogenesis
  • Middle Aged
  • Male
  • Lung Neoplasms
  • Immunotherapy, Adoptive